Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alonefollowing Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer(NSCLC)

Project: Research project

Project Details

Description

Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
StatusFinished
Effective start/end date1/1/18 → 8/31/24

Funding

  • BIG TEN CANCER RESEARCH CONSORTIUM
  • BRISTOL-MYERS SQUIBB PHARM RES

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint